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Author' s Reply
As noted in the commentary, the American Society of Clinical Oncology and College of American Pathologists (ASCO/ CAP) guideline recommendations for estrogen receptor (ER) and progesterone receptor (PR) positivity were revised from 10% to 1% in 2010 [1] . Patients with breast cancer in this study underwent primary surgery and biopsy for distant metastasis from 2000 to 2010 and the cutoff value for ER and PR positivity was 10% [2] . Many studies on patients with breast cancer before 2010 defined ER and PR positivity as ≥ 10% of tumor cells positive for nuclear staining [3, 4] . Furthermore, other studies reported that weakly ER/PR-positive breast cancer that had 1% to 10% positivity showed a survival rate intermediate between those of strongly ER-positive and ER-negative breast cancers [5] . Therefore, I agree that a cutoff value for ER and PR positivity should be 1% after a new guideline is established. However, as our study included patients before 2010, this cutoff value is acceptable for this study.
